icon-facebookicon-instagramicon-pinteresticon-soundcloudicon-twittericon-youtube
AMaRC 18-02 - RECRUITMENT OPENED

STATUS

Actively recruiting

Recruitment updated as of May 2021

 

STUDY TITLE

A prospective Phase II study of Isatuximab Rescue for Inadequate response to Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma (IRIL)

 

STUDY DESIGN

Prospective, multicentre, open label trial, phase II study 

 

CORRELATIVE STUDIES

Blood and bone marrow samples will be collected as part of the trial to assess the immunological, epigenetics and molecular profile 

 

TRIAL PRINCIPAL INVESTIGATOR

Professor Hang Quach

 

TIME FRAME

2018 – 2022

 

PARTICIPANTS

Newly diagnosed multiple myeloma patients who are ineligible for high-dose chemotherapy and autologous stem cell transplant 

 

CURRENT ENROLMENT

38

 

STATUS

Recruiting  

 

SITE LOCATIONS